Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.

Literature DB >> 22298820

Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.

Oliver Hantschel.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2012 PMID： 22298820 PMCID： PMC3269471 DOI： 10.3324/haematol.2012.061812

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

19 in total

Review 1. The molecular biology of chronic myeloid leukemia.

Authors: M W Deininger; J M Goldman; J V Melo
Journal: Blood Date: 2000-11-15 Impact factor: 22.113

2. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Authors: Ian J Griswold; Mary MacPartlin; Thomas Bumm; Valerie L Goss; Thomas O'Hare; Kimberly A Lee; Amie S Corbin; Eric P Stoffregen; Caitlyn Smith; Kara Johnson; Erika M Moseson; Lisa J Wood; Roberto D Polakiewicz; Brian J Druker; Michael W Deininger
Journal: Mol Cell Biol Date: 2006-08 Impact factor: 4.272

3. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.

Authors: Francisco J Adrián; Qiang Ding; Taebo Sim; Anastasia Velentza; Christine Sloan; Yi Liu; Guobao Zhang; Wooyoung Hur; Sheng Ding; Paul Manley; Jürgen Mestan; Doriano Fabbro; Nathanael S Gray
Journal: Nat Chem Biol Date: 2006-01-15 Impact factor: 15.040

4. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.

Authors: Brian J Skaggs; Mercedes E Gorre; Ann Ryvkin; Michael R Burgess; Yongming Xie; Yun Han; Evangelia Komisopoulou; Lauren M Brown; Joseph A Loo; Elliot M Landaw; Charles L Sawyers; Thomas G Graeber
Journal: Proc Natl Acad Sci U S A Date: 2006-12-12 Impact factor: 11.205

Review 6. Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.

Authors: Fabian Lang; Lydia Wunderle; Heike Pfeifer; Susanne Schnittger; Gesine Bug; Oliver G Ottmann
Journal: Am J Case Rep Date: 2017-10-16

6 in total

Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.

Review 1. The molecular biology of chronic myeloid leukemia.

2. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

3. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.

4. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.

5. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.

Review 6. Regulation of the c-Abl and Bcr-Abl tyrosine kinases.

7. Structural basis for the autoinhibition of c-Abl tyrosine kinase.

8. A myristoyl/phosphotyrosine switch regulates c-Abl.

9. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

10. Activation of tyrosine kinases by mutation of the gatekeeper threonine.

1. Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase.

Review 2. Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer.

3. Structure, regulation, signaling, and targeting of abl kinases in cancer.

Review 4. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.

5. Cell biology: a key driver of therapeutic innovation.

Review 6. Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.